Researchers identify mutations that can lead to resistance to some chemotherapies

Investigators at Mass General Brigham have uncovered how resistance to chemotherapies may occur in some cancers. Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study found that mutations to VPS35, a key player in this pathway, can prevent chemotherapy-induced cell death. These results, published in Nature, could help pinpoint treatment-resistant tumors.

Study reveals how Chagas parasite invades human cells

Researchers from Auburn University, in a landmark collaboration with Brazil’s Oswaldo Cruz Foundation (FIOCRUZ), the world’s leading research institution on Chagas Disease, have published a significant study in the journal Biochemistry. The study sheds new light on how the Chagas Disease parasite invades human cells—a crucial step towards developing effective treatments for this neglected tropical disease.

How melanoma and other tumors succeed in hiding and resisting immunotherapy

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of mutations. Although some of these alterations should be recognized as a threat by our defenses, melanomas often escape immune system surveillance. As a result, more than half of patients do not generally respond to current immunotherapies. Understanding and avoiding this phenomenon is one of the greatest challenges in oncology today.